Current Report Filing (8-k)
September 17 2020 - 4:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 14, 2020
APPLIED GENETIC TECHNOLOGIES CORPORATION
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-36370
|
|
59-3553710
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification Number)
|
14193 NW 119th Terrace
Suite 10
Alachua,
Florida, 32165
(Address of principal executive offices) (Zip Code)
(386) 462-2204
(Registrants telephone number, including area code)
Not Applicable
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to
Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.001 par value
|
|
AGTC
|
|
Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
|
|
|
|
|
|
|
|
|
|
Emerging growth company
|
|
☐
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On September 14, 2020, the compensation committee of the board of
directors of Applied Genetic Technologies Corporation (the Company) approved additional compensation to be provided to Mark Shearman, the Companys chief scientific officer. This compensation will accrue for the benefit of
Dr. Shearman as an additional payment of $15,000 per month effective beginning on July 1, 2020 and continuing through the month in which the Company hires a chief medical officer (such month, the Final Payment Month).
The accrued payments will be payable by the Company to Dr. Shearman on a quarterly basis, with the payment of the aggregate amount
accrued during each fiscal quarter payable on the last business day of such quarter, subject to Dr. Shearmans continued employment with the Company through and including such payment date. If the Final Payment Month is not the last month
of a fiscal quarter, then the Company will pay any accrued but unpaid payments on the last business day of the Final Payment Month, subject to Dr. Shearmans continued employment with the Company through and including such payment date.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
|
|
APPLIED GENETIC TECHNOLOGIES CORPORATION
|
|
|
By:
|
|
/s/ William A. Sullivan
|
|
|
William A. Sullivan
|
|
|
Chief Financial Officer
|
Date: September 17, 2020
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Applied Genetic Technolo... (NASDAQ:AGTC)
Historical Stock Chart
From Sep 2023 to Sep 2024